Ratio Revelations: CytomX Therapeutics Inc (CTMX)’s Financial Metrics in the Spotlight

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

CytomX Therapeutics Inc (NASDAQ: CTMX) closed the day trading at $1.75 up 2.94% from the previous closing price of $1.70. In other words, the price has increased by $2.94 from its previous closing price. On the day, 1.24 million shares were traded. CTMX stock price reached its highest trading level at $1.8 during the session, while it also had its lowest trading level at $1.69.

Ratios:

For a better understanding of CTMX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.

On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.

Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 19 ’24 when McCarthy Sean A. sold 20,223 shares for $2.09 per share. The transaction valued at 42,175 led to the insider holds 524,481 shares of the business.

BELVIN MARCIA sold 12,795 shares of CTMX for $26,684 on Mar 19 ’24. The SVP, Chief Scientific Officer now owns 168,579 shares after completing the transaction at $2.09 per share. On Mar 19 ’24, another insider, Landau Jeffrey B, who serves as the Chief Business Officer of the company, sold 6,562 shares for $2.09 each. As a result, the insider received 13,685 and left with 110,060 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 136358944 and an Enterprise Value of -1053104. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.14. Its current Enterprise Value per Revenue stands at -0.009 whereas that against EBITDA is -0.082.

Stock Price History:

Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -21.21%, while the 200-Day Moving Average is calculated to be 3.45%.

Shares Statistics:

Over the past 3-months, CTMX traded about 6.39M shares per day on average, while over the past 10 days, CTMX traded about 1582940 shares per day. A total of 77.92M shares are outstanding, with a floating share count of 72.40M. Insiders hold about 7.08% of the company’s shares, while institutions hold 64.95% stake in the company. Shares short for CTMX as of 1715731200 were 8748328 with a Short Ratio of 1.37, compared to 1713139200 on 3593963. Therefore, it implies a Short% of Shares Outstanding of 8748328 and a Short% of Float of 11.310001.

Most Popular